Nuvation Bio, Inc. (NUVB)
Total Valuation
Nuvation Bio has a market cap or net worth of $587.08 million. The enterprise value is -$112.03 million.
| Market Cap | 587.08M |
| Enterprise Value | -112.03M |
Important Dates
The latest earnings date was Wednesday, August 10, 2022, before market open.
| Last Earnings Date | Aug 10, 2022 |
| Ex-Dividend Date | n/a |
Share Statistics
Nuvation Bio has 218.24 million shares outstanding. The number of shares has increased by 6.17% in one year.
| Shares Outstanding | 218.24M |
| Shares Change (YoY) | +6.17% |
| Shares Change (QoQ) | +1.50% |
| Owned by Insiders (%) | 26.93% |
| Owned by Institutions (%) | 76.80% |
| Float | 112.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.85 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 33.58, with a Debt / Equity ratio of 0.01.
| Current Ratio | 33.58 |
| Quick Ratio | 33.08 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is -14.10% and return on invested capital (ROIC) is -18.00%.
| Return on Equity (ROE) | -14.10% |
| Return on Assets (ROA) | -13.60% |
| Return on Capital (ROIC) | -18.00% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.21M |
| Employee Count | 85 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.51% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | -67.51% |
| 50-Day Moving Average | 3.33 |
| 200-Day Moving Average | 4.49 |
| Average Volume (30 Days) | 1,172,143 |
Short Selling Information
The latest short interest is 9.53 million, so 4.37% of the outstanding shares have been sold short.
| Short Interest | 9.53M |
| Short % of Shares Out | 4.37% |
| Short % of Float | 8.46% |
| Short Ratio (days to cover) | 7.12 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -118.46M |
| Net Income | -103.26M |
| EBITDA | -102.81M |
| EBIT | -103.26M |
| Earnings Per Share (EPS) | -$0.42 |
Balance Sheet
The company has $703.80 million in cash and $4.69 million in debt, giving a net cash position of $699.10 million or $3.20 per share.
| Cash & Cash Equivalents | 703.80M |
| Total Debt | 4.69M |
| Net Cash | 699.10M |
| Net Cash Per Share | $3.20 |
| Book Value | 693.08M |
| Book Value Per Share | 3.18 |
| Working Capital | 692.99M |
Cash Flow
In the last 12 months, operating cash flow was -$88.48 million and capital expenditures -$366,000, giving a free cash flow of -$88.84 million.
| Operating Cash Flow | -88.48M |
| Capital Expenditures | -366,000 |
| Free Cash Flow | -88.84M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nuvation Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -17.59% |
| FCF Yield | -15.13% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.17% |
| Shareholder Yield | -6.17% |
Analyst Forecast
The average price target for Nuvation Bio is $13.94, which is 418.22% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.94 |
| Price Target Difference | 418.22% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |